A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-α treatment

Psychosomatics

Volumn 51, Issue 2, 2010, Pages 137-148

  Pierucci Lagha, Amira ^o   Covault, Jonathan ^o   Bonkovsky, Herbert L ^o   Feinn, Richard ^o   Abreu, Christine ^o   Sterling, Richard K ^o   Fontana, Robert J ^o   Kranzler, Henry R ^o   Szabo, Gyongyi ^a   Cormier, Maureen ^a   Giansiracusa, Donna ^a   Kelley, Michelle ^b   DiBisceglie, Adrian M ^c   Bacon, Bruce ^c   Neuschwander Tetri, Brent ^c   King, Debra ^c   Dienstag, Jules L ^d   Reid, Andrea E ^d   Chung, Raymond T ^d   Molchen, Wallis A ^d   Everson, Gregory T ^e   De Santo, Jennifer ^e   McKinley, Carol ^e   Morgan, Timothy R ^f   Hoefs, John C ^f   Park, Choon ^f   Lee, William M ^g   Shelton, Janel ^g   Crowder, Nicole ^g   Elbein, Rivka ^g   Lindsay, Karen L ^h   Jones, Carol B ^h   Milstein, Susan L ^h   Lok, Anna S F ⁱ   Richtmyer, Pamela A ⁱ   Shiffman, Mitchell L ^j   Hofmann, Charlotte ^j   Smith, Paula ^j   Ghany, Marc G ^k   Liang, T Jake ^k   Park, Yoon ^k   Rivera, Elenita ^k   Haynes Williams, Vanessa ^k   Everhart, James E ^k   Seeff, Leonard B ^k   Robuck, Patricia R ^k   Hoofnagle, Jay H ^k   Wright, Elizabeth C ^k   Morishima, Chihiro ^l   Gretch, David R ^l   Chung, Minjun ^l   Padmanabhan, Latha ^m   Curto, Teresa M ^m   Massey, Linda J ^m   Goodman, Zachary D ⁿ   Davis, Gary L ^o   Garcia Tsao, Guadalupe ^o   Kutner, Michael ^o   Lemon, Stanley M ^o   Perrillo, Robert P ^o   more..

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF TEXAS AT DALLAS   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^j VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^k NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

^m NEW ENGLAND RESEARCH INSTITUTES   (United States)

ⁿ ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^o Armed Forces Institute of Pathology ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DNA POLYMORPHISM; DRUG EFFECT; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 77949867445     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.51.2.137     Document Type: Article

References (53)

1. Alter MJ: Epidemiology of hepatitis C in the west. Semin Liver Dis 1995; 15:5-14
2. Alter MJ: Epidemiology of hepatitis C. Hepatology 1997; 26: 62S-65S
3. Davis GL: Current treatment for chronic hepatitis C. Rev Gastroenterol Disord 2001; 1:59-72
4. Alter MJ, Mast EE: The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437- 455
5. Poynard T, Leroy V, Cohard M, et al: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778-789
6. Manns MP, McHutchison JG, Gordon SC, et al: Peg-interferon alfa-2b-plus-ribavirin compared with interferon alfa-2b-plusribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965
7. Zeuzem S, Feinman SV, Rasenack J, et al: Peg-interferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672
8. Fried MW, Shiffman ML, Reddy KR, et al: Peg-interferon alfa-2a-plus-ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982
9. Zdilar D, Franco-Bronson K, Buchler N, et al: Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31:1207-1211
10. Castera L, Zigante F, Bastie A, et al: Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology 2002; 35:978-979
11. Hauser P, Khosla J, Aurora H, et al: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7:942-947
12. Dieperink E, Ho SB, Tetrick L, et al: Suicidal ideation during interferon-alpha2b-and-ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004; 26:237-240
13. Kraus MR, Wilms K: [Interferon alpha: effect, indications, therapy monitoring, and side-effects.] Internist (Berl) 2000; 41:1399-1404
14. Maes M, Bonaccorso S, Marino V, et al: Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry 2001; 6:475-480
15. Bonaccorso S, Marino V, Puzella A, et al: Increased depressive ratings in patients with hepatitis C receiving interferon-alphabased immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22:86-90
16. Miyaoka H, Otsubo T, Kamijima K, et al: Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156:1120
17. Capuron L, Miller AH: Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004; 56:819-824
18. Dang Y, Dale WE, Brown OR: Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radic Biol Med 2000; 28:615-624
19. Sakash JB, Byrne GI, Lichtman A, et al: Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-associated cells: implications for persistent chlamydophila pneumoniae infection. Infect Immun 2002; 70:3959-3961
20. Capuron L, Ravaud A, Neveu PJ, et al: Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7:468-473
21. Levenson JL, Fallon HJ: Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88:760-761
22. Schramm TM, Lawford BR, Macdonald GA, et al: Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173:359-361
23. Kraus MR, Schafer A, Faller H, et al: Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16:1091-1099
24. Capuron L, Gumnick JF, Musselman DL, et al: Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26:643-652
25. Mann JJ, Huang YY, Underwood MD, et al: A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000; 57:729-738
26. Lotrich FE, Pollock BG: Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet 2004; 14:121-129
27. Lesch KP, Bengel D, Heils A, et al: Association of anxietyrelated traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274:1527-1531
28. Nakamura M, Ueno S, Sano A, et al: The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5:32-38
29. Hu XZ, Lipsky RH, Zhu G, et al: Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78:815-826
30. Roy A, Hu XZ, Janal MN, et al: Interaction between childhood trauma and serotonin transporter gene variation in suicide. Neuropsychopharmacology 2007; 32:2046-2052
31. Hu XZ, Rush AJ, Charney D, et al: Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007; 64:783-792
32. Lee WM, Dienstag JL, Lindsay KL, et al: Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25:472-492
33. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al: Peg-interferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-1023
34. Wittchen HU: Reliability and validity studies of the World Health Organization Composite International Diagnostic Interview (CIDI): a critical review. J Psychiatr Res 1994; 28:57-84
35. Skinner HA, Sheu WJ: Reliability of alcohol use indices: The Lifetime Drinking History and the MAST. J Stud Alcohol 1982; 43:1157-1170
36. Beck A, Steer R, Brown G: Manual for the Beck Depression Inventory, 2nd Ed. San Antonio, TX, The Psychological Corporation; 1996
37. Hu X, Oroszi G, Chun J, et al: An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res 2005; 29:8-16
38. Littell R, Milliken G, Stroup W, et al: SAS System for Mixed Models. Cary, NC, SAS Institute Inc; 1996
39. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157:867-876
40. Dieperink E, Ho SB, Thuras P, et al: A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44:104-112
41. Kraus MR, Al-Taie O, Schafer A, et al: Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007; 132:1279-1286
42. Capuron L, Neurauter G, Musselman DL, et al: Interferon-alphainduced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54: 906-914
43. Morikawa O, Sakai N, Obara H, et al: Effects of interferon-alpha, interferon-gamma, and CAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998; 349:317-324
44. Tsao CW, Lin YS, Cheng JT, et al: Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol 2006; 63:106-115
45. Kraus MR, Schafer A, Al-Taie O, et al: Prophylactic SSRI during interferon alpha: therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepatol 2005; 12:96-100
46. Smeraldi E, Zanardi R, Benedetti F, et al: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3:508-511
47. Benedetti F, Serretti A, Colombo C, et al: Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry 1999; 156:1450-1452
48. Zanardi R, Benedetti F, Di Bella D, et al: Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20:105-107
49. Pollock BG, Ferrell RE, Mulsant BH, et al: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23:587-590
50. Yu YW, Tsai SJ, Chen TJ, et al: Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7:1115-1119
51. Rausch JL, Johnson ME, Fei YJ, et al: Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002; 51:723-732
52. Loftis JM, Socherman RE, Howell CD, et al: Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 2004; 365: 87-91
53. Yang BZ, Zhao H, Kranzler HR, et al: Practical population group assignment with selected informative markers: characteristics and properties of bayesian clustering via structure. Genet Epidemiol 2005; 28:302-312